Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer

Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer

ObjectiveThis study aims to evaluate the cost-effectiveness of using cadonilimab plus chemotherapy compared to chemotherapy in HER-2-negative advanced gastric cancer from the perspective of the Chinese healthcare system.MethodsA cost-effectiveness analysis was conducted utilizing a partitioned survi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Longfeng Zhang, Qingsheng Yang, Zhiwei Zheng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Public Health
Subjects:	advanced gastric cancer cadonilimab chemotherapy cost-effectiveness analysis HER-2-negative
Online Access:	https://www.frontiersin.org/articles/10.3389/fpubh.2025.1644176/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
by: Zhifeng Zhou, et al.
Published: (2025-05-01)

Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer
by: Kaixuan Wang, et al.
Published: (2025-06-01)

Efficacy prediction of neoadjuvant cadonilimab plus FLOT therapy for advanced gastric cancer: a study based on body composition changes
by: Penghui Liu, et al.
Published: (2025-08-01)

Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
by: Zuojuan Xiang, et al.
Published: (2025-07-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma
by: Liangliang Zou, et al.
Published: (2025-05-01)

Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy
by: Jianquan Yang, et al.
Published: (2025-07-01)

A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report
by: Haijuan Yu, et al.
Published: (2024-11-01)

Pyrotinib monotherapy for advanced HER2-positive esophageal adenocarcinoma with trastuzumab resistance and chemotherapy intolerance: a case report and literature review
by: Tao Wang, et al.
Published: (2025-03-01)

Clinical progress of cadonilimab in the treatment of malignant tumor
by: ZHANG Xiaoqing, et al.
Published: (2025-06-01)

Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration
by: Du Feng, et al.
Published: (2024-12-01)

Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases
by: Hai-Zhen Yi, et al.
Published: (2025-07-01)

Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial
by: Yiling Ding, et al.
Published: (2025-12-01)

Clinical efficacy and safety of Cadonilimab in the treatment of advanced gynecological malignancies: a retrospective, real-world study
by: Yisidan Huang, et al.
Published: (2025-08-01)

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)
by: H. C. Chung, et al.
Published: (2017-02-01)

Cadonilimab combined with trastuzumab and chemotherapy for HER2-positive gastric cancer with bone marrow metastasis and DIC: a case report and literature review
by: Meijing Chen, et al.
Published: (2025-06-01)

First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution
by: Guillermo Valencia, et al.
Published: (2024-12-01)

Patient with HR-proficient advanced ovarian cancer achieved a complete response with Cadonilimab combined chemotherapy (PD-1/CTLA-4 bispecific): a case report and literature review
by: Chenge Zhang, et al.
Published: (2025-08-01)

Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
by: Shixian Liu, et al.
Published: (2025-08-01)

Real-time assessment of circulating tumor cells refines the indication for HER2-targeted therapy in metastatic gastric cancer
by: Yasuaki Kimura, et al.
Published: (2025-07-01)

The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis
by: Sedat Yıldırım, et al.
Published: (2025-05-01)

Efficacy and safety of oxaliplatin and capecitabine in combination with sintilimab as first-line treatment for HER2-negative advanced gastric cancer
by: ZHANG Xiaorui, SHAN Haixia, ZHU Zhengqiu
Published: (2025-01-01)

Inhibition of human gastric cancer growth by cytokine-induced killer cells plus chemotherapy with or without cadonilimab in a mouse xenograft tumor model
by: Wenwei Yang, et al.
Published: (2025-06-01)

THE ROLE OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER
by: A. A. Bobryshev, et al.
Published: (2021-03-01)

Timing of postoperative chemotherapy and prognosis in neoadjuvant-treated gastric cancer patients: a multicenter real-world cohort study
by: Hua-Long Zheng, et al.
Published: (2025-12-01)

Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study
by: Bin Yin, et al.
Published: (2025-01-01)

Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab
by: Toshihiko Matsumoto, et al.
Published: (2025-08-01)

Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
by: Yilin Wang, et al.
Published: (2025-04-01)

Feasibility and predictive factors on the completion of docetaxel plus S‐1 adjuvant chemotherapy in pathological stage III gastric cancer
by: Masayoshi Terayama, et al.
Published: (2025-01-01)

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial
by: Yaofei Jiang, et al.
Published: (2025-03-01)

Successful subtotal gastrectomy and hepatectomy for HER2-positive gastric cancer with liver metastasis after trastuzumab-based chemotherapy: a case report
by: Yuki Hirase, et al.
Published: (2024-03-01)

Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer
by: Jun Yao, et al.
Published: (2025-05-01)

Analysis of the Clinical Molecular Characteristics and Neoadjuvant Chemotherapy Response in Patients with Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer and Axillary Lymph Node Metastasis
by: Jin-Ping Ma, et al.
Published: (2022-06-01)

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
by: Vincenzo Nasca, et al.
Published: (2025-04-01)

Challenges in treating coexisting scrotal apocrine carcinoma and gastric cancer: insights from an elderly patient: a case report and literature review
by: Boyan Huang, et al.
Published: (2024-10-01)

The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists
by: L. G. Zhukova, et al.
Published: (2020-06-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

Programmed death‐ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2‐negative status
by: Lei Wang, et al.
Published: (2018-06-01)

Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study
by: Jian Chen, et al.
Published: (2025-07-01)

Effectiveness and safety of combined treatment with herbal medicines and palliative chemotherapy for advanced gastric cancer: A systematic review and meta-analysis
by: Dong-Hyeon Kim, et al.
Published: (2025-03-01)

Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy
by: Tomoyuki Satake, et al.
Published: (2024-12-01)